Upadacitinib Delivers Rapid Response in Ulcerative Colitis

Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.

Related Keywords

California ,United States ,San Diego ,Milan ,Lombardia ,Italy ,Ann Arbor ,Michigan ,Silvio Danese ,Peter Higgins ,Siddharth Singh ,University Of California ,York University Langone Health ,Genentech ,Research Center ,University Of Michigan ,Pfizer ,American College Of Gastroenterology ,Astrazeneca ,Humanitas Clinical ,American College ,New York University Langone Health ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Colitis ,Ulcerative Colitis ,Neoadjuvant ,Remission ,Clinical Research ,Clinical Trials ,Linical Studies ,Biologic Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Generics ,Generic Drug ,Eneric Medication ,Neutropenia ,Activism ,Activist ,Adverse Effects ,Side Effects , ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Cv ,Ardiovascular ,